XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1Close
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Net sales $ 4,120 $ 3,599 $ 7,977 $ 6,988
Cost of products sold 1,270 1,058 2,479 2,098
Gross profit 2,850 2,542 5,498 4,891 Close
Operating expenses:         Close
Selling, general and administrative expenses 1,446 1,354 2,810 2,570 Close
Research and development expenses 383 359 749 695 Close
Royalty expense 9 12 19 23 Close
Amortization expense 213 210 427 412 Close
Intangible asset impairment charges 276 57 276 57 Close
Contingent consideration net expense (benefit) 2 19 18 31 Close
Restructuring net charges (credits) 1 16 5 36 Close
Operating expenses 2,330 2,028 4,303 3,825 CloseClose
Operating income (loss) 520 514 1,195 1,066 Close
Other income (expense):         Close
Interest expense (77) (70) (146) (135) CloseCloseCloseCloseCloseCloseCloseCloseClose
Other, net (23) (18) (21) (61) CloseCloseCloseCloseCloseCloseCloseCloseCloseClose
Total Other Income Expenses 320.0 338.0 861.0 674.0 0.0 Close
Income (loss) before income taxes 420 426 1,028 870 CloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseClose
Income tax expense (benefit) 98 156 213 287 Close
Net income (loss) 322 270 815 584 Close
Preferred stock dividends 0 (9) 0 (23)
Net income (loss) attributable to noncontrolling interests (2) 0 (4) 0
Net income (loss) attributable to Boston Scientific common stockholders $ 324 $ 261 $ 819 $ 561
Net income (loss) per common share — basic $ 0.22 $ 0.18 $ 0.56 $ 0.39
Net income (loss) per common share — diluted $ 0.22 $ 0.18 $ 0.55 $ 0.39
Weighted-average shares outstanding        
Basic 1,470.6 1,446.2 1,469.5 1,441.0
Diluted 1,484.2 1,456.2 1,483.0 1,451.1